Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.03. | Bioventus CFO sells over $29k in company stock | 1 | Investing.com | ||
20.03. | Bioventus executive sells over $6,600 in company stock | 1 | Investing.com | ||
20.03. | Bioventus exec sells over $17k in company stock | 1 | Investing.com | ||
20.03. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
13.03. | Bioventus shares target raised to $9 on solid Q4 performance | 1 | Investing.com | ||
13.03. | Earnings call: Bioventus Inc. reports solid Q4 growth, optimistic 2024 outlook | 1 | Investing.com | ||
12.03. | Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday | 1 | Benzinga.com | ||
12.03. | Bioventus Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
12.03. | Bioventus Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
12.03. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.03. | Bioventus Non-GAAP EPS of $0.07 beats by $0.05, revenue of $135.42M beats by $11.46M | 1 | Seeking Alpha | ||
12.03. | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results | - | GlobeNewswire (USA) | ||
11.03. | A Preview Of Bioventus' Earnings | 1 | Benzinga.com | ||
18.01. | Bioventus, Inc.: Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility | 251 | GlobeNewswire (Europe) | DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered... ► Artikel lesen | |
12.01. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.01. | Bioventus, Inc.: Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole | 4 | GlobeNewswire (USA) | ||
09.01. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
21.12.23 | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.12.23 | Bioventus names Medtronic, J&J veteran as CEO | 15 | MassDevice | ||
19.12.23 | Bioventus appoints Robert Claypoole as president and CEO | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,920 | -2,54 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
GINKGO BIOWORKS | 0,925 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
ONCOLYTICS BIOTECH | 0,975 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 26,310 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
ASSERTIO | 0,754 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
SIGA TECHNOLOGIES | 8,240 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
MERRIMACK PHARMACEUTICALS | 14,680 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 7,960 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
VERVE THERAPEUTICS | 6,660 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
ARS PHARMACEUTICALS | 8,450 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
BIO-PATH | 4,200 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent Portfolio | HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop... ► Artikel lesen | |
BIOMEA FUSION | 11,160 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |